JP Morgan Upgrades Health Catalyst to Overweight, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anne Samuel has upgraded Health Catalyst (HCAT) from Neutral to Overweight while reducing the price target from $14 to $11.
December 13, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Health Catalyst was upgraded by JP Morgan from Neutral to Overweight, indicating a positive outlook, but the price target was lowered from $14 to $11, suggesting some caution.
The upgrade to Overweight implies that JP Morgan sees potential in Health Catalyst's stock, which could lead to increased investor interest and a potential short-term price increase. However, the reduction in the price target to $11 reflects a tempered expectation for the stock's performance, which might moderate the positive impact of the upgrade.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100